Evotec ESG Presentation Deck
evotec
Precision
Human genetics supported targets¹)
% success
PAGE 5
2x
All programmes Genetically supported
Biomarker based stratification²)
No biomarker
Delivering what the industry and patients really need
Patient & disease relevance, conscious use of resources, higher returns
3x
Selection biomarker
+
Efficiency
Average project evaluation time
in months before R&D decision ³)
8
Average project
Average cost to safety4)
(FGLPD) in %
100
-75%
Average project
-50%
2
Evotec project
50
Evotec project
¹) Margan, P. et al. Nature Rev Drug Discovery 2018 Mar 17 (3): 167-181
2) Evotec-Bayer report "Excelling Together for the Benefit of Women Suffering from Endometriosis
3) Deloitte Report Unlocking R&D Productivity, Measuring the Return from Pharmaceutical Innovation 2019
II
Capitalised cost per launch,
in US$ bn4)
Target
LO Pre-
clinical
Clinical
2x
4) Evotec internal; Paul S.et al Nature Rev. Drug Discov. 9 203-214 (2010).
McKinsey 2014 McKinsey one advantage to product launch (2014).
FGLPD = First good laboratory practice dose in safety assessment.
LaunchView entire presentation